Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.AstraZeneca and Forest Laboratoriesare are set to commence phase III trials to test the efficacy of ceftazidime/avibactam (CAZ-AVI) to treat Gram-negative bacterial infections.
Subscribe to our email newsletter
The infections include Complicated Intra-Abdominal Infections (cIAI) and Complicated Urinary Tract Infections (cUTI).
CAZ-AVI comprises cephalosporin (ceftazidime) and a novel beta-lactamase inhibitor (avibactam), which helps overcome antibiotic-resistance and treat the infections resistant to existing therapies.
This study comprises two separate CAZ-AVI phase II trials.
The cIAI Phase II trial showed that the efficacy of CAZ-AVI given with metronidazole in adult patients was similar to meropenem, a treatment given to patients with Complicated Intra-Abdominal Infections.
The cUTI Phase II trial showed that the efficacy of CAZ-AVI in adult patients was similar to imipenem cilastatin, which is given to patients with Complicated Urinary Tract Infections.